Drug intelligence / Profile preview

HPG5119

Development stage: Unknown
Lead developer: Hepagene Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

HPG5119 is an investigational oral small molecule developed by Hepagene Therapeutics. It acts as a Glucagon-like peptide 1 receptor (GLP-1R) agonist. The drug is currently in Phase 2 clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on HPG5119.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HPG5119.

Explore the full profile